Exicure Inc (XCUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Exicure Inc (XCUR) has a cash flow conversion efficiency ratio of -0.908x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-887.00K) by net assets ($977.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Exicure Inc market capitalisation for the company's overall valuation and market capitalisation.
Exicure Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Exicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Exicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exicure Inc ranked by their cash flow conversion efficiency. Explore XCUR cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sharc International Systems
F:IWIA
|
0.409x |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
-0.021x |
|
Orient Press Limited
NSE:ORIENTLTD
|
0.114x |
|
Federal International Holdings Bhd
KLSE:8605
|
-0.049x |
|
Kesla Oyj A
HE:KELAS
|
0.068x |
|
Asmallworld AG
SW:ASWN
|
0.480x |
|
Crown Point Energy Inc
V:CWV
|
-0.370x |
|
Locate Technologies Ltd
AU:LOC
|
-0.104x |
Annual Cash Flow Conversion Efficiency for Exicure Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Exicure Inc from 2015 to 2025. View XCUR stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.93 Million | $-8.55 Million | -2.179x | -407.10% |
| 2024-12-31 | $6.77 Million | $-2.91 Million | -0.430x | +87.42% |
| 2023-12-31 | $3.03 Million | $-10.36 Million | -3.417x | -42.99% |
| 2022-12-31 | $14.92 Million | $-35.66 Million | -2.390x | +22.91% |
| 2021-12-31 | $11.23 Million | $-34.82 Million | -3.100x | -385.53% |
| 2020-12-31 | $61.51 Million | $-39.27 Million | -0.638x | -4014.57% |
| 2019-12-31 | $80.75 Million | $1.32 Million | 0.016x | +101.75% |
| 2018-12-31 | $20.95 Million | $-19.49 Million | -0.930x | +6.12% |
| 2017-12-31 | $19.98 Million | $-19.79 Million | -0.991x | +51.98% |
| 2016-12-31 | $2.45 Million | $-5.05 Million | -2.063x | -208.20% |
| 2015-12-31 | $18.23 Million | $-12.20 Million | -0.669x | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more